enGene injects new hope into the future of bladder cancer care
Ron Cooper, ex-Albireo CEO, is betting on enGene’s novel gene delivery platform to sidestep BCG shortfalls and transform bladder cancer treatment worldwide.
2 stories
Make us preferred on GoogleRon Cooper, ex-Albireo CEO, is betting on enGene’s novel gene delivery platform to sidestep BCG shortfalls and transform bladder cancer treatment worldwide.
“I think I'm blessed with truly the best team in all of pharma… we are doing something that's bigger than all of us!”
London · 15–19 November 2026
Explore Onyx’s independent guide to the events and make the most of your week in London.